Department of Microbiology, School of Medicine, University of Patras, Patras, Greece.
Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, University of Patras, Patras, Greece.
J Med Microbiol. 2021 Sep;70(9). doi: 10.1099/jmm.0.001419.
Dalbavancin was approved in Europe in 2015 for skin and soft tissue infections. Data on methicillin-resistant coagulase-negative staphylococci (MR-CNS) dalbavancin susceptibility are scarce. To assess the susceptibility of MR-CNS to dalbavancin and other anti-staphylococcal agents. A total of 443 MR-CNS clinical isolates from patients hospitalized in a Greek university hospital during a 2.5-year period (January 2018 to June 2020) were included. The MICs for vancomycin, teicoplanin, linezolid and daptomycin were investigated by Etest and the MIC for dalbavancin was determined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines in 196 isolates. The consumption of the aforementioned antimicrobials was calculated. In total, 51 isolates were resistant to teicoplanin (11.5 %) and 211 (47.6 %) to linezolid; all were susceptible to vancomycin and daptomycin. Among 196 isolates tested, 32 (16.3 %) were resistant to dalbavancin. A significant increase of MIC during the study period was found for vancomycin, teicoplanin and daptomycin, while a decrease in linezolid's MIC was observed. Dalbavancin's MIC remained stable. No difference in consumption was observed among the studied anti-staphylococcal agents. An increase of vancomycin, teicoplanin and daptomycin MICs among MR-CNS was observed, whereas 47.6 % of isolates were non-susceptible to linezolid. Dalbavancin retains excellent potency against MR-CNS, even in the presence of non-susceptibility to other anti-staphylococcal antibiotics.
达巴万星于 2015 年在欧洲获批用于治疗皮肤和软组织感染。关于耐甲氧西林凝固酶阴性葡萄球菌（MR-CNS）对达巴万星敏感性的数据很少。评估 MR-CNS 对达巴万星和其他抗葡萄球菌药物的敏感性。共纳入了 2018 年 1 月至 2020 年 6 月期间在希腊一家大学医院住院的 443 例 MR-CNS 临床分离株。通过 Etest 检测万古霉素、替考拉宁、利奈唑胺和达托霉素的 MIC，根据欧洲抗菌药物敏感性试验委员会（EUCAST）指南测定了 196 株达巴万星的 MIC。计算了上述抗菌药物的消耗量。共有 51 株对替考拉宁耐药（11.5%），211 株对利奈唑胺耐药（47.6%）；所有菌株对万古霉素和达托霉素均敏感。在 196 株试验菌株中，有 32 株（16.3%）对达巴万星耐药。研究期间发现万古霉素、替考拉宁和达托霉素的 MIC 显著增加，而利奈唑胺的 MIC 下降。达巴万星的 MIC 保持稳定。在所研究的抗葡萄球菌药物中，没有观察到消耗量的差异。MR-CNS 中万古霉素、替考拉宁和达托霉素的 MIC 增加，而 47.6%的分离株对利奈唑胺不敏感。达巴万星对 MR-CNS 仍然具有出色的效力，即使在对其他抗葡萄球菌抗生素不敏感的情况下也是如此。
